Illumina (ILMN) will release TruSight Oncology 500 v2, a new version of its flagship cancer research assay to enable comprehensive genomic profiling. The assay is currently under development, with global
Illumina (ILMN) will release TruSight Oncology 500 v2, a new version of its flagship cancer research assay to enable comprehensive genomic profiling. The assay is currently under development, with global
“Tracker Quants” של Cantor Fitzgerald שיתפו את התחזית שלהם לסקירה הקרובה של מדד Nasdaq 100. Nasdaq יבצעו את האיזון השנתי של מדד 100 בסוף דצמבר 20, עם השינויים שיאושרו ב-13
Cantor Fitzgerald’s “Tracker Quants” laid out its forecasted changes for the upcoming Nasdaq 100 Index review. Nasdaq will implement its annual rebalance for its100 Index as of the close of
In a report released today, Patrick B Donnelly from Citi maintained a Buy rating on Illumina (ILMN – Research Report), with a price target of $190.00. The company’s shares closed
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by